A retrospective observational study of oral ivarmacitinib and narrow-band ultraviolet-B in refractory progressive vitiligo_supplementary material
收藏DataCite Commons2026-04-17 更新2026-05-04 收录
下载链接：
https://data.mendeley.com/datasets/rcb8ss6wv8
下载链接
链接失效反馈官方服务：
资源简介：
Supplementary methods
Supplementary Figure 1. Representative clinical photos of refractory vitiligo patients at the baseline and 12-week follow-up.
Supplementary Figure 2. Clinical outcomes during oral ivarmacitinib and narrow-band ultraviolet B (NB-UVB) therapy.
(a) The BSA involvement (%) at the baseline and 12-week follow-up. (b) The VASI at the baseline and 12-week follow-up. ****P ≤ 0.0001.
Supplementary Table 1. Adverse events related to ivarmacitinib among patients who applied ivarmacitinib throughout the study (baseline to week 12).
提供机构：
Mendeley Data
创建时间：
2026-04-17
